No Data
Novartis Says Talks for Prostate Cancer Treatment Fail to Secure Deal
Watching Incyte; Traders Circulate Research Report From Unemon Suggesting Novartis Emerges As The Ideal Acquirer, Says "Would Not Be Surprised To See A $105-$110 Deal In The Coming Weeks"
UBS Sticks to Their Buy Rating for Novartis AG (NOVN)
Novartis (NVS.US) has had its application for Lutetium [177Lu] oxodotreotide accepted by the Center for Drug Evaluation (CDE) for market approval.
Nuclear medicine, represented by radiopharmaceutical therapy, is an area where Novartis has heavily invested.
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details
Schrodinger Shares Are Trading Higher After the Company Raised Its FY24 Software Revenue Growth Guidance. Additioanlly, the Company Announced a Research Collaboration and License Agreement With Novartis to Advance Multiple Development Candidates.